Macter International Limited

MACTER

PK0113501016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
89.85 ^PKR	+3.74%		-0.17%	+2.10%

12/03	Macter International Limited Announces Board Changes	CI
09/01	Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	CI

Macter International Limited Announces Resignation of Syed Anis Ahmed Shah as Director

December 13, 2023 at 08:16 pm IST

Macter International Limited has announced the resignation of Syed Anis Ahmed Shah from his position as a director of the company, effective December 13, 2023. The company has stated that the casual vacancy created by this resignation will be filled by the Board of Directors in due course.

Latest news about Macter International Limited

Macter International Limited Announces Board Changes	12/03	CI
Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	09/01	CI
Macter International Limited Announces Resignation of Syed Anis Ahmed Shah as Director	13/12	CI
Macter International Limited Proposes Final Cash Dividend for the Financial Year Ending June 30, 2023	28/23/28	CI
Macter International Limited Announces Change of Director	08/23/08	CI
Macter International Limited Announces Cease of Tariq Wajid as Director	09/23/09	CI
Macter International Limited Announces Executive Changes	17/22/17	CI
Macter International Limited Announces Board Changes	21/22/21	CI
Macter International Limited Announces Cessation of Sohaib Umar as Director	25/21/25	CI
Macter International Limited Announces Unconsolidated Earnings Results for the Year Ended June 30, 2021	01/21/01	CI
Macter International Limited Recommends Cash Dividend for the Year Ended June 30, 2021	20/21/20	CI
Macter International Limited Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended December 31, 2020	17/21/17	CI
Macter International Limited Declares Interim Cash Dividend	17/21/17	CI
Macter International Limited Announces Unconsolidated and Consolidated Earnings Results for the Year Ended June 30, 2020	05/20/05	CI
Macter International Limited Reports Unaudited Un-Consolidated and Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2020	30/20/30	CI
Macter International Limited Reports Un-Consolidated and Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2019	26/20/26	CI
Macter International Limited Announces Unaudited Unconsolidated Earnings Results for the Quarter Ended September 30, 2019	29/19/29	CI
Macter International Limited Proposes Final Cash Dividend for the Year Ended June 30, 2019	04/19/04	CI
Macter International Limited Announces Earnings Results for the Year Ended June 30, 2019	04/19/04	CI
Macter International Limited Reports Unaudited Unconsolidated and Consolidated Earnings Results for the Quarter and Nine Months Ended March 31, 2019	30/19/30	CI
Macter International Limited Reports Un-Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2018	28/19/28	CI
Macter International Limited Reports Earnings Results for the Quarter Ended September 30, 2018	30/18/30	CI
Macter International Limited Reports Earnings Results for the Year Ended of June 30, 2018	04/18/04	CI
Macter International Limited Announces Executive Changes	04/18/04	CI
Macter International Limited Appoints Masarrat Misbah as its Director in Place of Muhammad Sajid	01/18/01	CI

Chart Macter International Limited

Duration

Period

More charts

Company Profile

Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Companyâs business areas are contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. The Company produces specialty products at its high-tech plant. These include solid and liquid oral dosage forms (tablets, capsules, syrups, suspensions and dry powder), injections (sterile liquid vials, sterile liquid ampoules and sterile dry powders), ointments and creams, drops and inhalers. Its manufacturing operations include formulation, vial filling, lyophilization and packaging of biological drugs.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MACTER INTERNATIONAL LIMITED	+2.10%	1.43Cr
ELI LILLY AND COMPANY	+33.15%	71TCr
NOVO NORDISK A/S	+30.77%	60TCr
JOHNSON & JOHNSON	-2.08%	37TCr
MERCK & CO., INC.	+20.03%	33TCr
ABBVIE INC.	+5.19%	29TCr
ASTRAZENECA PLC	+14.77%	24TCr
NOVARTIS AG	+9.13%	21TCr
ROCHE HOLDING AG	-3.97%	20TCr
AMGEN INC.	+9.42%	17TCr

Other Pharmaceuticals